Skip to main content
Erschienen in:

18.02.2022 | COVID-19 | DFP-Fortbildung

Update SARS-CoV-2 Behandlungsempfehlungen für die Intensivmedizin

verfasst von: Dr. Markus Köstenberger, Prim. Univ.-Prof. Dr. Walter Hasibeder, Dr. Daniel Dankl, Prim. Univ.-Prof. Dr. Philip Eisenburger, Prim. Univ.-Doz. Dr. Reinhard Germann, Dr. Wilhelm Grander, Prim. Assoc. Prof. Dr. Christoph Hörmann, Univ.-Prof. Dr. Michael Joannidis, Univ.-Prof. Dr. Klaus Markstaller, Dr. Steve-Oliver Müller-Muttonen, Dr. Stefan Neuwersch-Sommeregger, PD Dr. Bettina Pfausler, Dr. Otmar Schindler, Dr. Gregor Schittek, Assoc. Prof. PD Dr. Eva Schaden, Univ.-Prof. Dr. Thomas Staudinger, Ao. Univ.-Prof. Dr. Roman Ullrich, Dr. Matthias Urban, PhD, Univ.-Prof. Dr. Andreas Valentin, MBA, Prim. Univ.-Prof. Dr. Rudolf Likar

Erschienen in: Anästhesie Nachrichten | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Auszug

Der Anteil von SARS-CoV-2-positiven Patient*innen, die intensivmedizinisch betreut werden müssen, stellen eine große Herausforderung für das medizinische und pflegerische Personal dar. Aktuelle Guidelines unterstützen mit evidenzbasierten Empfehlungen den Umgang mit COVID-19-Patient*innen im intensivmedizinischen Setting, um die maximale Sicherheit der Patient*innen und des medizinischen Betreuungsteams gleichermaßen sicherzustellen. …
Literatur
1.
Zurück zum Zitat Köstenberger M, Hasibeder W, Dankl D, et al. SARS-CoV-2: recommendations for treatment in intensive care medicine. Wien Klin Wochenschr. 2020;132(21–22):664–70.PubMedPubMedCentral Köstenberger M, Hasibeder W, Dankl D, et al. SARS-CoV-2: recommendations for treatment in intensive care medicine. Wien Klin Wochenschr. 2020;132(21–22):664–70.PubMedPubMedCentral
2.
Zurück zum Zitat Alhazzani W, Evans L, Alshamsi F, et al. Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. Crit Care Med. 2021;49(3):e219–e34.PubMed Alhazzani W, Evans L, Alshamsi F, et al. Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. Crit Care Med. 2021;49(3):e219–e34.PubMed
3.
Zurück zum Zitat Kluge StJU, Welte T, et al. S3-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19. AWMF Online. 2021. Kluge StJU, Welte T, et al. S3-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19. AWMF Online. 2021.
4.
Zurück zum Zitat Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020;20(8):911–9.PubMedPubMedCentral Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020;20(8):911–9.PubMedPubMedCentral
5.
Zurück zum Zitat Wang Y, Liao B, Guo Y, et al. Clinical Characteristics of Patients Infected With the Novel 2019 Coronavirus (SARS-Cov-2) in Guangzhou, China. Open Forum Infect Dis. 2020;7(6):ofaa187.PubMedPubMedCentral Wang Y, Liao B, Guo Y, et al. Clinical Characteristics of Patients Infected With the Novel 2019 Coronavirus (SARS-Cov-2) in Guangzhou, China. Open Forum Infect Dis. 2020;7(6):ofaa187.PubMedPubMedCentral
6.
Zurück zum Zitat RKI. Epidemiologischer Steckbrief zu SARS-CoV‑2 und COVID-19. 2021. RKI. Epidemiologischer Steckbrief zu SARS-CoV‑2 und COVID-19. 2021.
7.
Zurück zum Zitat Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.PubMed Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.PubMed
8.
Zurück zum Zitat Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. JAMA. 2020;323(15):1499–500.PubMed Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. JAMA. 2020;323(15):1499–500.PubMed
9.
Zurück zum Zitat Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–42.PubMed Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–42.PubMed
10.
Zurück zum Zitat WHO. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. 2021. WHO. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. 2021.
11.
Zurück zum Zitat Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–82.PubMed Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–82.PubMed
12.
Zurück zum Zitat Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172–2181.e6.PubMed Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172–2181.e6.PubMed
13.
Zurück zum Zitat Oliveira E, Parikh A, Lopez-Ruiz A, et al. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. PLoS ONE. 2021;16(3):e249038.PubMedPubMedCentral Oliveira E, Parikh A, Lopez-Ruiz A, et al. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. PLoS ONE. 2021;16(3):e249038.PubMedPubMedCentral
14.
Zurück zum Zitat Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894–901.PubMed Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894–901.PubMed
15.
Zurück zum Zitat Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systematic review. J Med Virol. 2020;92(5):479–90.PubMedPubMedCentral Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systematic review. J Med Virol. 2020;92(5):479–90.PubMedPubMedCentral
16.
Zurück zum Zitat Roca O, Messika J, Caralt B, et al. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: the utility of the ROX index. J Crit Care. 2016;35:200–5.PubMed Roca O, Messika J, Caralt B, et al. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: the utility of the ROX index. J Crit Care. 2016;35:200–5.PubMed
17.
Zurück zum Zitat Nasa P, Azoulay E, Khanna AK, et al. Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method. Crit Care. 2021;25(1):106.PubMedPubMedCentral Nasa P, Azoulay E, Khanna AK, et al. Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method. Crit Care. 2021;25(1):106.PubMedPubMedCentral
18.
Zurück zum Zitat Roca O, Caralt B, Messika J, et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med. 2019;199(11):1368–76.PubMed Roca O, Caralt B, Messika J, et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med. 2019;199(11):1368–76.PubMed
19.
Zurück zum Zitat Prakash J, Bhattacharya PK, Yadav AK, Kumar A, Tudu LC, Prasad K. ROX index as a good predictor of high flow nasal cannula failure in COVID-19 patients with acute hypoxemic respiratory failure: A systematic review and meta-analysis. J Crit Care. 2021;66:102–8.PubMedPubMedCentral Prakash J, Bhattacharya PK, Yadav AK, Kumar A, Tudu LC, Prasad K. ROX index as a good predictor of high flow nasal cannula failure in COVID-19 patients with acute hypoxemic respiratory failure: A systematic review and meta-analysis. J Crit Care. 2021;66:102–8.PubMedPubMedCentral
20.
Zurück zum Zitat Pascarella G, Strumia A, Piliego C, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192–206.PubMed Pascarella G, Strumia A, Piliego C, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192–206.PubMed
22.
Zurück zum Zitat NIH. Covid-19 treatment guidelines. 2021. NIH. Covid-19 treatment guidelines. 2021.
24.
Zurück zum Zitat Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209–18.PubMedPubMedCentral Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209–18.PubMedPubMedCentral
25.
Zurück zum Zitat Hirsch JS, Ikizler TA, Sharma S, Mohammed A. Acute kidney injury and advanced kidney disease in the COVID-19 pandemic: proceedings from a national kidney foundation symposium. Kidney Med. 2021;3(3):426–32.PubMedPubMedCentral Hirsch JS, Ikizler TA, Sharma S, Mohammed A. Acute kidney injury and advanced kidney disease in the COVID-19 pandemic: proceedings from a national kidney foundation symposium. Kidney Med. 2021;3(3):426–32.PubMedPubMedCentral
26.
Zurück zum Zitat Joannidis M, Forni LG, Klein SJ, et al. Lung-kidney interactions in critically ill patients: consensus report of the acute disease quality initiative (ADQI) 21 workgroup. Intensive Care Med. 2020;46(4):654–72.PubMed Joannidis M, Forni LG, Klein SJ, et al. Lung-kidney interactions in critically ill patients: consensus report of the acute disease quality initiative (ADQI) 21 workgroup. Intensive Care Med. 2020;46(4):654–72.PubMed
27.
Zurück zum Zitat Nadim MK, Forni LG, Mehta RL, et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol. 2020;16(12):747–64.PubMedPubMedCentral Nadim MK, Forni LG, Mehta RL, et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol. 2020;16(12):747–64.PubMedPubMedCentral
28.
Zurück zum Zitat Investigators I, Sadeghipour P, Talasaz AH, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021;325(16):1620–30. Investigators I, Sadeghipour P, Talasaz AH, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021;325(16):1620–30.
29.
Zurück zum Zitat Investigators R‑C, Investigators AC‑a, Investigators A, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385(9):777–89. Investigators R‑C, Investigators AC‑a, Investigators A, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385(9):777–89.
30.
Zurück zum Zitat Cortegiani A, Ippolito M, Ingoglia G, Iozzo P, Giarratano A, Einav S. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. J Crit Care. 2020;59:176–90.PubMedPubMedCentral Cortegiani A, Ippolito M, Ingoglia G, Iozzo P, Giarratano A, Einav S. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. J Crit Care. 2020;59:176–90.PubMedPubMedCentral
31.
Zurück zum Zitat Consortium WHOST, Pan H, Peto R, et al. Repurposed antiviral drugs for Covid-19 – interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511. Consortium WHOST, Pan H, Peto R, et al. Repurposed antiviral drugs for Covid-19 – interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511.
32.
Zurück zum Zitat WHO. WHO COVID-19 solidarity therapeutics trial. 2021. WHO. WHO COVID-19 solidarity therapeutics trial. 2021.
33.
Zurück zum Zitat Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2):e00221-18. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2):e00221-18.
34.
Zurück zum Zitat de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020;117(12):6771–6.PubMedPubMedCentral de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020;117(12):6771–6.PubMedPubMedCentral
35.
Zurück zum Zitat Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Gotte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295(15):4773–9.PubMedPubMedCentral Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Gotte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295(15):4773–9.PubMedPubMedCentral
36.
Zurück zum Zitat Ko WC, Rolain JM, Lee NY, et al. Arguments in favour of remdesivir for treating SARS-CoV‑2 infections. Int J Antimicrob Agents. 2020;55(4):105933.PubMedPubMedCentral Ko WC, Rolain JM, Lee NY, et al. Arguments in favour of remdesivir for treating SARS-CoV‑2 infections. Int J Antimicrob Agents. 2020;55(4):105933.PubMedPubMedCentral
37.
Zurück zum Zitat Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV‑2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12(541):eabb5883. Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV‑2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12(541):eabb5883.
38.
Zurück zum Zitat Pruijssers AJ, George AS, Schafer A, et al. Remdesivir inhibits SARS-coV‑2 in human lung cells and chimeric SARS-coV expressing the SARS-coV‑2 RNA polymerase in mice. Cell Rep. 2020;32(3):107940.PubMedPubMedCentral Pruijssers AJ, George AS, Schafer A, et al. Remdesivir inhibits SARS-coV‑2 in human lung cells and chimeric SARS-coV expressing the SARS-coV‑2 RNA polymerase in mice. Cell Rep. 2020;32(3):107940.PubMedPubMedCentral
39.
Zurück zum Zitat Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.PubMedPubMedCentral Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.PubMedPubMedCentral
40.
Zurück zum Zitat Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.PubMedPubMedCentral Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.PubMedPubMedCentral
41.
Zurück zum Zitat Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med. 2020;383(19):1813–26.PubMed Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med. 2020;383(19):1813–26.PubMed
42.
Zurück zum Zitat Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019;169:104541.PubMedPubMedCentral Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019;169:104541.PubMedPubMedCentral
43.
Zurück zum Zitat Group RC, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. Group RC, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704.
44.
Zurück zum Zitat Villar J, Ferrando C, Martinez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267–76.PubMed Villar J, Ferrando C, Martinez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267–76.PubMed
45.
Zurück zum Zitat Investigators R‑C, Gordon AC, Mouncey PR, et al. Interleukin‑6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491–502. Investigators R‑C, Gordon AC, Mouncey PR, et al. Interleukin‑6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491–502.
46.
Zurück zum Zitat Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–45. Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–45.
47.
Zurück zum Zitat Guimaraes PO, Quirk D, Furtado RH, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385(5):406–15.PubMed Guimaraes PO, Quirk D, Furtado RH, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385(5):406–15.PubMed
48.
Zurück zum Zitat Kalil AC, Stebbing J. Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. Lancet Respir Med. 2021;9(12):1349-1351. Kalil AC, Stebbing J. Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. Lancet Respir Med. 2021;9(12):1349-1351.
49.
Zurück zum Zitat Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795–807.PubMed Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795–807.PubMed
Metadaten
Titel
Update SARS-CoV-2 Behandlungsempfehlungen für die Intensivmedizin
verfasst von
Dr. Markus Köstenberger
Prim. Univ.-Prof. Dr. Walter Hasibeder
Dr. Daniel Dankl
Prim. Univ.-Prof. Dr. Philip Eisenburger
Prim. Univ.-Doz. Dr. Reinhard Germann
Dr. Wilhelm Grander
Prim. Assoc. Prof. Dr. Christoph Hörmann
Univ.-Prof. Dr. Michael Joannidis
Univ.-Prof. Dr. Klaus Markstaller
Dr. Steve-Oliver Müller-Muttonen
Dr. Stefan Neuwersch-Sommeregger
PD Dr. Bettina Pfausler
Dr. Otmar Schindler
Dr. Gregor Schittek
Assoc. Prof. PD Dr. Eva Schaden
Univ.-Prof. Dr. Thomas Staudinger
Ao. Univ.-Prof. Dr. Roman Ullrich
Dr. Matthias Urban, PhD
Univ.-Prof. Dr. Andreas Valentin, MBA
Prim. Univ.-Prof. Dr. Rudolf Likar
Publikationsdatum
18.02.2022
Verlag
Springer Vienna
Erschienen in
Anästhesie Nachrichten / Ausgabe 1/2022
Print ISSN: 2617-2127
Elektronische ISSN: 2731-3972
DOI
https://doi.org/10.1007/s44179-022-00019-9

Weitere Artikel der Ausgabe 1/2022

Anästhesie Nachrichten 1/2022 Zur Ausgabe

Editorial

OPG-Update

Editorial

ÖGARI-Update

Kongressbericht: 4. Österreichischer Palliativtag

Was darf (Palliativ-)Medizin?

Neu im Fachgebiet AINS

Schläge auf den Rücken sind die beste Erste Hilfe

11.07.2024 Techniken in der Notfallmedizin Nachrichten

Bei der Aspiration eines Fremdkörpers mit Verschluss der Atemwege ist rasche Hilfe erforderlich. Doch welche Methode verspricht den meisten Erfolg? Eine Studie aus Kanada hat drei Techniken miteinander verglichen.

Bewusstsein während Reanimation – gibt es "typische" Fälle?

10.07.2024 Kardiopulmonale Reanimation Nachrichten

Australische Rettungsdienstdaten deuten darauf hin, dass sich Fälle, in denen eine laufende Reanimation Anzeichen von Bewusstsein induziert, von anderen Wiederbelebungsfällen unterscheiden könnten. Etwa mit Blick auf die Überlebenschancen.

Cholestatische Hepatitis durch Syphilis

09.07.2024 Treponema pallidum Nachrichten

Ein Mann kommt mit Gelbsucht in die Notaufnahme. In der Klinik wird eine cholestatische Hepatitis festgestellt, die Ursache bleibt zunächst jedoch im Dunklen. Erst ein Sehschärfenverlust durch ein Retinaödem weist auf den Auslöser: Treponema pallidum.

Engpass-Syndrom als Rückenschmerz-Ursache oft übersehen?

04.07.2024 Nacken- und Rückenschmerz Nachrichten

Hinter anhaltenden Rückenschmerzen im Bereich der Lendenwirbel könnte ein Engpass-Syndrom der oberen Gesäßnerven stecken. Wie eine Studie aus Istanbul nahelegt, wird dieses in der Praxis möglicherweise häufig übersehen.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.